Related Experiment Videos
The effect of thyroid function on clinical outcome in patients with heart failure
Shmuel Chen1, Ayelet Shauer, Donna R Zwas
1Heart Failure Center, Heart Institute, Hadassah University Hospital, Jerusalem, Israel.
Insights
Elevated thyroid-stimulating hormone (TSH) levels in heart failure (HF) patients predict increased mortality and hospitalizations. Monitoring TSH is crucial for managing HF outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Internal Medicine
Background:
- Thyroid dysfunction impacts cardiac function and is a heart failure risk factor.
- Limited data exists on thyroid-stimulating hormone (TSH) as an isolated predictor of outcomes in heart failure (HF) patients.
Purpose of the Study:
- To evaluate the clinical significance of TSH levels as a predictor of outcomes in a large cohort of patients with chronic heart failure.
Main Methods:
- A cohort of 5599 heart failure patients was followed for cardiac-related hospitalizations and death.
- Patients were stratified into quartiles based on TSH levels.
- Cox regression analysis was used to assess the association between TSH levels and mortality, adjusting for other predictors.
Main Results:
- Both high and low TSH levels correlated with increased mortality.
- The highest TSH quartile showed a significant association with increased mortality (HR 1.36, P=0.01).
- TSH was an independent predictor of death and cardiac-related hospitalization, particularly in patients not on levothyroxine treatment.
Conclusions:
- Elevated TSH levels are linked to worse clinical outcomes in heart failure patients.
- Thyroid imbalance presents a significant risk in heart failure and requires clinical attention.
Aims:
Thyroid dysfunction is known to effect cardiac function and is a risk factor for developing heart failure (HF). Data regarding the clinical significance of thyroid-stimulating hormone (TSH) levels alone as a predictor of outcome in patients with HF is sparse. We evaluated the significance of TSH on clinical outcome in a large cohort of patients with chronic HF.
Methods And Results:
Patients with a diagnosis of HF at a Health Maintenance Organization (n = 5599) were followed for cardiac-related hospitalizations and death. Median TSH levels were 2.2 mIU/L (interquartile range 1.4-3.5). We divided patients into quartiles based on TSH levels. Median follow-up time was 434 days and the overall mortality rate was 13.2%. Both a high and a low TSH level was associated with an increased mortality rate. Cox regression analysis after adjustment for other significant predictors demonstrated that the highest TSH quartile was associated with increased mortality compared with those with the lowest mortality [second quartile: TSH 1.4-2.2 mIU/L, hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.08-1.71, P = 0.01]. TSH was also an independent predictor of death and cardiac-related hospitalization. Analysis of patients not on levothyroxine treatment (78%) demonstrated that TSH was an even stronger predictor of mortality (HR 1.54, 95% CI 1.17-2.03, P = 0.002). Additional analysis based on accepted clinical cut-offs of TSH demonstrated that increasing TSH levels above normal were independently associated with increased mortality and cardiac-related hospitalizations.
Conclusions:
Increased TSH levels are associated with worse clinical outcome in patients with HF. Thyroid imbalance confers significant risk in HF and warrants attention.
Related Concept Videos
Heart Failure I: Introduction
Hyperthyroidism II: Pathophysiology
Heart Failure Drugs: β-Blockers
Hypothyroidism II: Pathophysiology
Heart Failure III: Clinical Manifestations
Heart Failure VII: Nursing Interventions